Antibiotics After Breast Reduction:Clinical Trial With Randomization
Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Oct 5, 2015
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Prevention of SSI is important due to its morbidity, longer hospital stays and higher costs. In many surgical procedures where the risk of infection is relatively low and the postoperative infection can be treated properly, the role of antibiotics is not clear.
Despite the lack of evidence from prospective randomized controlled trials of evaluation, the use of antibiotics in plastic surgery is widespread in order to offer the highest safety standards patients.
The breast reduction is defined as "clean surgery" with a lower infection rate to 3.4%. Thus, the antibiotic is not recommended. H...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast hypertrophy
- • Body mass index between 19 to 30 kg/m2
- Exclusion Criteria:
- • Patients undergoing a surgical procedure in the breast
- • Diagnosis of breast pathology
- • Smoking
- • Childbirth or lactation less than a year
- • Uncontrolled comorbidities
- • Use of immunosuppressive drugs
- • Misuse of capsules supplied
- • Absence during the weekly follow-up
About Federal University Of São Paulo
The Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP) is a prestigious institution dedicated to advancing education, research, and healthcare in Brazil. Renowned for its commitment to innovation and excellence, UNIFESP plays a pivotal role in clinical research, focusing on a multidisciplinary approach to improve health outcomes. The university fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that clinical trials conducted under its auspices adhere to rigorous ethical standards and contribute valuable insights to the medical field. With a rich history of academic achievement and a strong emphasis on translational research, UNIFESP is a key player in the development of new therapies and medical interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pouso Alegre, Minas Gerais, Brazil
Patients applied
Trial Officials
Lydia M Ferreira, PhD
Study Chair
Federal University of São Paulo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials